Treatment patterns for neovascular age-related macular degeneration: Analysis of 284 380 medicare beneficiaries

American Journal of Ophthalmology

Volumn 153, Issue 6, 2012, Pages 1116-1124.e1

  Curtis, Lesley H ^a,b   Hammill, Bradley G ^a   Qualls, Laura G ^a   Dimartino, Lisa D ^a   Wang, Fang ^d   Schulman, Kevin A ^a,b   Cousins, Scott W ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

ACUTE HEART INFARCTION; AFRICAN AMERICAN; AGED; ARTICLE; CATARACT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DEMENTIA; DIABETES MELLITUS; DRUG USE; EUROPEAN AMERICAN; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEOPLASM; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PREDICTION; PRIORITY JOURNAL; RACE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT WITHDRAWAL; TREND STUDY;

EID: 84862789005     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2011.11.032     Document Type: Article

References (35)

1. D.S. Friedman, B.J. O'Colmain, B. Munoz Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 4 2004 564 572
2. F.L. Ferris 3rd, S.L. Fine, L. Hyman Age-related macular degeneration and blindness due to neovascular maculopathy Arch Ophthalmol 102 11 1984 1640 1642
3. R.D. Jager, W.F. Mieler, J.W. Miller Age-related macular degeneration N Engl J Med 358 24 2008 2606 2617
4. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report Arch Ophthalmol 117 10 1999 1329 1345
5. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr, M. Feinsod, D.R. Guyer Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 27 2004 2805 2816
6. P. Mitchell, J.F. Korobelnik, P. Lanzetta Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials Br J Ophthalmol 94 1 2010 2 13
7. P. Abraham, H. Yue, L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 Am J Ophthalmol 150 3 2010 315 324.e1
8. H. Dadgostar, A.A.C.M. Ventura, J.Y. Chung, S. Sharma, P.K. Kaiser Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 9 2009 1740 1747
9. U. Schmidt-Erfurth, B. Eldem, R. Guymer Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 5 2011 831 839
10. CATT Research Group D.F. Martin, M.G. Maguire et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
11. ClinicalTrials.gov Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial http://www.clinicaltrials.gov/ct2/ show/NCT00593450 Accessed: September 5, 2010
12. ClinicalTrials.gov Clinical Assessment of Age-Related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab (COMPASS) http://clinicaltrials.gov/ct2/show/NCT01402544 Accessed: September 5, 2011
13. ClinicalTrials.gov Lucentis in Advanced Macular Degeneration http://clinicaltrials.gov/ct2/show/NCT00896779 Accessed: September 5, 2011
14. ClinicalTrials.gov Evaluation of Dosing Interval of Higher Doses of Ranibizumab (BGB/IST) http://clinicaltrials.gov/ct2/show/NCT00533520 Accessed: September 5, 2011
15. ClinicalTrials.gov A Study of Ranibizumab Administered Monthly or on an As-Needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR) http://clinicaltrials.gov/ct2/show/NCT00891735 Accessed: September 5, 2011
16. R.J. Brechner, P.J. Rosenfeld, J.D. Babish, S. Caplan Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file Am J Ophthalmol 151 5 2011 887 895.e1
17. D.S. Fong, P. Custis, J. Howes, J.W. Hsu Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study Ophthalmology 117 2 2010 298-230
18. ClinicalTrials.gov LUCAS (Lucentis Compared to Avastin Study) http://clinicaltrials.gov/ct2/show/NCT01127360 Accessed: September 5, 2011
19. ClinicalTrials.gov French Evaluation Group Avastin Versus Lucentis (GEFAL) http://clinicaltrials.gov/ct2/show/NCT01170767 Accessed: September 5, 2011
20. ClinicalTrials.gov Bevacizumab versus Ranibizumab in Age Related Macular Degeneration (AxL-2009) http://clinicaltrials.gov/ct2/show/NCT01014468 Accessed: September 5, 2011
21. Centers for Medicare & Medicaid Services Medicare Part B Drug Average Sales Price http://www.cms.gov/McrPartBDrugAvgSalesPrice/01-overview.asp Accessed: June 21, 2010
22. Chronic Condition Data Warehouse: User Manual http://ccwdata.org/ downloads/CCW-UserManual.pdf Accessed: June 21, 2010
23. J.D. Kalbfleisch, R.L. Prentice The Statistical Analysis of Failure Time Data 1980 Wiley New York
24. D. Ghosh, D.Y. Lin Nonparametric analysis of recurrent events and death Biometrics 56 2 2000 554 562
25. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, M.K. Ezzat, R.J. Singh Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 12 2007 2179 2182
26. M.A. Chang, H.F. Fine, E. Bass Patients' preferences in choosing therapy for retinal vein occlusions Retina 27 6 2007 789 797
27. A.E. Fung, G.A. Lalwani, P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 4 2007 566 583
28. R.A. Mittra, J.S. Pollack ASRS Preferences and Trends Survey, 2008 2008 American Society of Retina Specialists Chicago, IL
29. D. Iturralde, R.F. Spaide, C.B. Meyerle Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study Retina 26 3 2006 279 284
30. A.A. Moshfeghi, P.J. Rosenfeld, C.A. Puliafito Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study Ophthalmology 113 11 2006 2002.e1 2002.e12
31. R.M. Rich, P.J. Rosenfeld, C.A. Puliafito Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 5 2006 495 511
32. R.F. Spaide, K.M. Laud, H.F. Fine Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 4 2006 383 390
33. L.H. Curtis, B.G. Hammill, K.A. Schulman, S.W. Cousins Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration Arch Ophthalmol 128 10 2010 1273 1279
34. Y. Imamura, M. Engelbert, T. Iida, K.B. Freund, L.A. Yannuzzi Polypoidal choroidal vasculopathy: a review Surv Ophthalmol 55 6 2010 501 515
35. J.C. Javitt, Z. Zhou, M.G. Maguire, S.L. Fine, R.J. Willke Incidence of exudative age-related macular degeneration among elderly Americans Ophthalmology 110 8 2003 1534 1539